411 related articles for article (PubMed ID: 10982256)
41. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma.
Vose JM; Bierman PJ; Lynch JC; Atkinson K; Juttner C; Hanania CE; Bociek G; Armitage JO
Biol Blood Marrow Transplant; 2001; 7(12):680-7. PubMed ID: 11787531
[TBL] [Abstract][Full Text] [Related]
42. Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment.
Villalón L; Odriozola J; Laraña JG; Zamora C; Pérez de Oteyza J; Jodra MH; López J; Herrera P; Roldán E; Ramos ML; Ramos P; Navarro JL
Hematol J; 2000; 1(6):374-81. PubMed ID: 11920217
[TBL] [Abstract][Full Text] [Related]
43. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
44. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
45. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
46. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system.
Rowley SD; Loken M; Radich J; Kunkle LA; Mills BJ; Gooley T; Holmberg L; McSweeney P; Beach K; MacLeod B; Appelbaum F; Bensinger WI
Bone Marrow Transplant; 1998 Jun; 21(12):1253-62. PubMed ID: 9674860
[TBL] [Abstract][Full Text] [Related]
47. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
48. Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery.
McNiece I; Briddell R; Stoney G; Kern B; Zilm K; Recktenwald D; Miltenyi S
J Hematother; 1997 Feb; 6(1):5-11. PubMed ID: 9112213
[TBL] [Abstract][Full Text] [Related]
49. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
[TBL] [Abstract][Full Text] [Related]
50. Factors that influence collection and engraftment of autologous peripheral-blood stem cells.
Bensinger W; Appelbaum F; Rowley S; Storb R; Sanders J; Lilleby K; Gooley T; Demirer T; Schiffman K; Weaver C
J Clin Oncol; 1995 Oct; 13(10):2547-55. PubMed ID: 7595706
[TBL] [Abstract][Full Text] [Related]
51. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
[TBL] [Abstract][Full Text] [Related]
52. Positive selection of autologous peripheral blood stem cells.
Lopez M; Beaujean F
Baillieres Best Pract Res Clin Haematol; 1999; 12(1-2):71-86. PubMed ID: 11000984
[TBL] [Abstract][Full Text] [Related]
53. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients.
Richel DJ; Johnsen HE; Canon J; Guillaume T; Schaafsma MR; Schenkeveld C; Hansen SW; McNiece I; Gringeri AJ; Briddell R; Ewen C; Davies R; Freeman J; Miltenyi S; Symann M
Bone Marrow Transplant; 2000 Feb; 25(3):243-9. PubMed ID: 10673694
[TBL] [Abstract][Full Text] [Related]
54. CD34+ cell dose and CD33- subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation.
Sampol Mayol A; Besalduch Vital J; Galmés Llodrá A; Bargay Lleonart J; Matamoros Flori N; Morey Sureda M; Novo García A; Mascaró Riera M; Gonzaléz Bach E; Martínez García P
Haematologica; 1998 Jun; 83(6):489-95. PubMed ID: 9676020
[TBL] [Abstract][Full Text] [Related]
55. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD
Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876
[TBL] [Abstract][Full Text] [Related]
56. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
Sawada H; Wake A; Yamasaki Y; Izumi Y
Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
[TBL] [Abstract][Full Text] [Related]
57. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.
Koç ON; Gerson SL; Phillips GL; Cooper BW; Kutteh L; Van Zant G; Reece DE; Fox RM; Schupp JE; Tainer N; Lazarus HM
Bone Marrow Transplant; 1998 Feb; 21(4):337-43. PubMed ID: 9509966
[TBL] [Abstract][Full Text] [Related]
58. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
59. [Clinical study on single-dose rhG-CSF combined with chemotherapy in autologous peripheral blood stem cell transplantation].
Tian H; Zhou SY
Ai Zheng; 2002 Aug; 21(8):896-9. PubMed ID: 12478902
[TBL] [Abstract][Full Text] [Related]
60. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
